ATPW
MRKR icon

Ashton Thomas Private Wealth’s Marker Therapeutics MRKR Stock Holding History

Ashton Thomas Private Wealth’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3K Buy
16,400
+6,400
+64% +$10.2K ﹤0.01% 1348
2025
Q4 		$14.9K Hold
10,000
– – ﹤0.01% 995
2025
Q3 		$8.93K Buy
+10,000
New +$12.3K ﹤0.01% 965

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Ashton Thomas Private Wealth's MRKR Position: Q1 2026 in Review

Ashton Thomas Private Wealth increased its Marker Therapeutics (MRKR) stake by 64% in Q1 2026, buying an estimated $10.2K and bringing the position to 16,400 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1348.

Ashton Thomas Private Wealth first reported a position in MRKR in Q3 2025 and has held it in 3 quarters since. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Ashton Thomas Private Wealth held 16,400 shares of Marker Therapeutics worth $21.3K as of Q1 2026.
  • Ashton Thomas Private Wealth bought 6,400 Marker Therapeutics shares in Q1 2026, an estimated $10.2K.
  • Marker Therapeutics made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #1348 holding.
  • Ashton Thomas Private Wealth first reported a position in Marker Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.